바이오인

 

At 31-years old, biotechnology has reached a point where it has "come of age" and now it's on to the maturing years. We've seen evidence of strengthening pipelines, revenue growth, and progress towards profitability. This is often when challenges emerge that are the result of success. Challenges born from the convergence in time of innovative new products, newly profitable companies, and escalating regulatory challenges.

 

Reflecting on 2006, Looking Ahead for 2007. In this year’s "Beyond Borders" report, biotech and pharmaceuticals executives and global financial experts analyze the economic motivation, political environment, and cultural diversity that shaped record-breaking revenue and investment numbers around the world in 2006.

 

Regional Reporting. Articles that on specific regions offer in-depth reporting and opinions that can help executives, analysts, and investors better understand an industry that’s becoming a regulation minefield while at the same time offering spectacular rewards to those who can successfully navigate the field.

 

Commercialization Trends, Deal Making, and CEO Survey Results. Highlights from "Beyond Borders" include outtakes from two roundtables and a survey of top CEOs and executives sharing their perspectives on product commercialization trends, deals, and just what keeps them up at night. Key topics covered include:

 

  Best practices for bringing a product to market

  Product launch risks and pitfalls

  In-house launch vs. partnering

  Impact of regulatory "fourth hurdle"

  Reimbursement strategy

 

  Deal flow and promising industry segments

  Acquisition premiums as a trend

  Challenges for buyers and sellers in the current environment

  Best practices to mitigate risk

  Implications of increased buyer competition

  Early-stage deals and their risks

  Trading sales instead of IPOs for exits

  Two-Year Growth Plan and Key Challenges

  More than 400 responses by company executives from the US, Europe, and Canada

  Data regarding hiring expectations, M&A plans, global expansion, outsourcing, and

  regulatory challenges